Engflag

Zozo

Quick links to important sections

Zozo

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zozo

Property Description
Active ingredient Alprazolam and Zolpidem
Form Oral Tablet/Capsule
Pharmacological class Central Nervous System (CNS) Depressant
General purpose Promotes calmness and facilitates sleep
Origin Synthetic

What Type of Medicine is Zozo?

Zozo is a specialized, synthetic combination product classified generally as a Central Nervous System (CNS) Depressant. This classification reflects its fundamental action of reducing excessive neuronal activity in the brain and spinal cord. The medicine is intended for oral intake and is typically manufactured as a tablet or capsule. As it contains Alprazolam, a widely studied agent, the formulation is clinically recognized as containing a component from the benzodiazepine class. This status places the medication strictly within the confines of a prescription-only product.

Composition: Alprazolam and Zolpidem as Active Ingredients

The two active ingredients in Zozo are the international nonproprietary names (INN) Alprazolam and Zolpidem. Alprazolam functions primarily as an anxiolytic, aimed at reducing nervous tension. Zolpidem is classified as a non-benzodiazepine sedative-hypnotic agent, commonly referred to as a Z-drug, specifically designed to facilitate sleep onset. The hypnotic action of Zolpidem is associated with reducing the time required to fall asleep. The core composition is defined by this dual-agent approach, utilizing both the broader anti-anxiety properties and the targeted sleep-promoting effects of its components.

General Purpose of the Dual-Agent Formulation

The overall purpose of Zozo is to provide an integrated approach for co-occurring symptoms, particularly when an individual experiences underlying nervousness or tension coupled with significant difficulty falling asleep. The formulation leverages the anxiolytic action to foster a state of calmness, while simultaneously utilizing the potent hypnotic action to successfully promote rest. By combining agents that respectively promote calmness and sedation, the medicine is positioned to quiet overactive brain function and help achieve stability.

Regulatory References

  1. NIH MedlinePlus on Alprazolam

What side effects are possible with Zozo?

Possible Side Effects and Safety Information

Adverse reactions associated with this medicine primarily reflect its status as a Central Nervous System (CNS) depressant. The official safety profile is organized into categories of frequency, organ systems affected, and critical safety constraints.

Commonly Documented Adverse Reactions

The most frequently observed effects in clinical studies include somnolence (drowsiness), dizziness, headache, fatigue, and impaired coordination. Other effects commonly listed in regulatory documents include memory impairment (amnesia), dry mouth, constipation, and diarrhea. These reactions largely fall under the Nervous System Disorders and Gastrointestinal Disorders system-organ classes.

Serious Adverse Reactions and Constraints

Critical, though often less frequent, safety events are explicitly documented in regulatory labeling. These include the risk of Complex Sleep Behaviors (such as sleep-driving or performing activities while not fully awake, which can result in serious injury). The potential for profound sedation and respiratory depression is a major constraint, particularly when the medicine is used with alcohol or other CNS depressants, which is officially recognized as substantially increasing risk.

Safety Patterns and Special Populations

The medicine is associated with a risk of developing physical dependence and subsequent withdrawal symptoms upon rapid dose reduction or abrupt cessation. Regulatory bodies mandate specific considerations for certain patient groups, noting that older adults are more susceptible to impaired cognitive and motor performance. Furthermore, use is subject to restrictions in individuals with severe hepatic impairment due to altered drug clearance.

Next-Day Impairment is a noted safety pattern, as the CNS depressant effects may persist into the morning after use, an effect that is more pronounced with higher doses.

Overdose and Emergency Response

The official regulatory profile for a Zozo overdose focuses on the risk of progressive Central Nervous System (CNS) Depression. Documented clinical manifestations can include states of somnolence, confusion, lethargy, impaired coordination (ataxia), and diminished reflexes.

The most severe outcomes listed in regulatory documents are life-threatening: they include respiratory depression, profound hypotension (low blood pressure), cardiovascular impairment, and coma, all of which pose a risk of a fatal outcome. The severity of overdose is explicitly noted to be increased in the elderly and in cases of co-ingestion with alcohol or other CNS depressant medications.

Immediate medical attention must be sought upon any suspicion of overdose. Regulatory mandates require that emergency services or a poison control center be contacted immediately due to the risk of rapid progression to severe symptoms. Management is officially defined as symptomatic and supportive treatment, which includes continuous monitoring of vital signs and maintenance of respiration. The specific antagonist, Flumazenil, may be employed, but official labeling provides specific cautions regarding its use in overdose situations.

Therapeutic Uses of Zozo

What Zozo Treats: Main Uses and Benefits

The primary purpose of Zozo is to provide symptomatic relief in clinical settings where a patient is dealing with co-occurring nervous tension and symptoms related to sleep difficulty. Its dual composition is applied across domains where short-term, supportive assistance in symptom stabilization is appropriate, relevant for managing symptoms that interfere with daily comfort. The formulation includes a component applied in addressing symptoms related to anxiety and panic disorder, while the other component is considered relevant for short-term insomnia treatment.

The medication is commonly used to help manage symptoms related to Generalized Anxiety Disorder and short-term insomnia.

Easing Symptoms of Anxiety-Induced Sleeplessness

This domain covers the simultaneous presence of symptoms related to heightened physiological activity, such as mental agitation, and sleep onset issues. Zozo is relevant in situations where symptoms cluster into patterns requiring integrated supportive management, helping address symptoms that create noticeable physiological strain. The medication supports general well-being by offering symptomatic relief that helps patients cope more steadily with difficult episodes of tension.

Symptom Focus: Nervous Tension The medication is commonly used to help manage symptoms related to excessive worry and agitation, may assist with functional stability when symptoms become more noticeable.

Short-Term Support for Heightened Symptoms

Zozo is commonly used in clinical settings characterized by acute or disruptive symptom patterns and where supportive symptom management is appropriate. It is applied when pronounced symptoms of anxiety and sleeplessness create noticeable functional strain. The medication may assist with temporary assistance in symptom stabilization, which supports patients during difficult episodes by helping with distress.

Regulatory References

  1. NIH MedlinePlus overview of Alprazolam

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zozo

This section summarizes the official population eligibility and non-eligibility rules for Zozo as documented in government regulatory sources. These rules are based on the constraints of its two active ingredients, Alprazolam and Zolpidem.

Category Official Regulatory Status
Populations for whom use is allowed: Adults without contraindicating conditions.
Populations for whom use is not recommended: Pediatric patients (under 18); Nursing mothers; Patients with a history of substance abuse/dependence.
Populations for whom use is contraindicated: Hypersensitivity to components; Acute narrow-angle glaucoma; Severe hepatic impairment; History of complex sleep behaviors after zolpidem use; Patients taking strong CYP3A inhibitors.

Official eligibility is strictly defined by age and specific health conditions. The medicine is not established as safe or effective in pediatric patients and is not recommended for this age group. Geriatric patients may use the medicine but are classified as especially sensitive and require a lower starting dosage. Patients with impaired renal function or compromised respiratory function (e.g., sleep apnea) should use the medicine with caution. During pregnancy, use is conditional, permitted only if the potential benefit justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official interaction profile for Zozo (Alprazolam and Zolpidem) is defined by both pharmacodynamic reinforcement and pharmacokinetic clearance patterns, as outlined in regulatory documentation.

Property Official Regulatory Information
Medicinal product categories with documented interactions Strong/Potent CYP3A Inhibitors, CYP3A Inducers, Opioids, Other CNS Depressants (e.g., Antipsychotics, Anticonvulsants).
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic Interaction via inhibition or induction of the Cytochrome P450 CYP3A/CYP3A4 enzyme system. Pharmacodynamic Interaction via additive CNS depressant effects.
Timing-based interaction rules (if applicable) The product should not be administered with or immediately after a meal for the Zolpidem component, as food is documented to delay the onset of hypnotic effects.
Population-specific interaction notes (if applicable) Use with caution in patients with Severe Hepatic Impairment, where substantially slower clearance and increased plasma concentrations of Zolpidem are documented.

Resulting Interaction Structure

Co-administration with the potent CYP3A inhibitors Ketoconazole and Itraconazole is officially contraindicated due to the substantial, documented increase in alprazolam plasma concentrations. Concomitant use with Opioids is subject to regulatory warnings regarding the risk of profound sedation and respiratory depression due to additive pharmacodynamic effects. Other strong CYP3A inhibitors (e.g., Nefazodone, Fluvoxamine, Erythromycin) result in a documented increase in exposure. Conversely, CYP3A inducers (e.g., Carbamazepine, Rifampin) are documented to reduce exposure, potentially compromising efficacy. The use of Alcohol is documented to cause an additive adverse effect on psychomotor performance.

Mechanism of Action

How Zozo Works

Zozo operates by engaging precise mechanisms to influence components within overactive or dysregulated physiological pathways, primarily through receptor- or enzyme-mediated signaling. This action modifies early molecular steps and subsequent signaling sequences to alter activity profiles within targeted biological pathways.

Modulation of Specific Signaling Mediators

Zozo's core action involves modifying early molecular steps within systems where specific transmitters or mediators dominate. This domain covers the targets responsible for initiating or suppressing the signaling sequences that lead to downstream physiological effects, influencing the activity of processes driven by distinct signaling patterns. Zozo may function as an antagonist or partial agonist depending on the specific receptor or enzyme interaction profile.

Influence on Physiological Response Pathways

The drug's effect extends to modulating key pathways associated with heightened physiological responses. By engaging mechanisms that influence feedback regulation within these cascades, Zozo decreases the signaling output resulting from excessive mediator activity. This results in physiological adjustments that affect the magnitude of pathway response, contributing to overall system-level modulation.

Dosage and Administration Information

How Zozo is Used: Administration Guidelines

Zozo is an oral medication that combines Alprazolam and Zolpidem, and its usage is guided by the clinical guidelines for these individual components. The administration guidelines define the specific route, dose, frequency, duration, and patient-specific adjustments required for its use.

Dosing and Scheduling

Zozo must be taken orally in tablet or capsule form. The dosing schedule is defined by the component's purpose:

Component Focus Standard Adult Dosing Principles Frequency and Timing
Anxiety (Alprazolam) Starting dose: 0.25 mg to 0.5 mg. Maximum daily dose up to 4 mg for Generalized Anxiety Disorder. Typically taken in divided doses multiple times a day (e.g., three times daily).
Insomnia (Zolpidem) Starting dose: 5 mg (women) or 5 mg to 10 mg (men). Maximum daily dose is 10 mg. Taken once nightly immediately before bedtime.

The Zolpidem component should be taken on an empty stomach to ensure faster effect and only when the patient is able to get a full 7 to 8 hours of sleep.

Use Duration and Specific Populations

Treatment with the Zolpidem component is intended to be short-term and should not exceed four weeks, including the necessary tapering period.

Discontinuation of the Alprazolam component requires a gradual reduction (tapering) of the dose to minimize risk, generally recommending a decrease of no more than 0.5 mg every 3 days.

Specific adjustments are mandated for certain groups. For older adults and patients with hepatic impairment, the initial oral dosage of both components is lower (e.g., 0.25 mg for Alprazolam and 5 mg for Zolpidem once daily). These rules ensure consistent administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zozo

Evidence for Managing Nervous Tension

The component of Zozo whose research examined outcomes related to symptoms of nervous tension and anxiety (the Alprazolam component) was evaluated in research for conditions like Generalized Anxiety Disorder and Panic Disorder. The research primarily consists of short-term, placebo-controlled clinical trials. Studies tracked outcomes related to physiological strain and measured changes in symptom severity using standardized clinical scales. Findings describe patterns observed in measurements of acute panic episodes during the studies.

Study Duration and Long-Term Follow-up Data

For both active components of Zozo, the research is primarily focused on short-term changes, generally spanning periods of four weeks to a few months. Evidence regarding the durability of response or the maintenance of measured outcomes over long durations (e.g., six months or more) is less well-characterized in controlled clinical trials. Scientific literature highlights this as an area of ongoing research, noting that long-term effects are not fully established regarding consistency of measurements and other physiological responses.

Evidence for Addressing Sleep Difficulty

The component of Zozo applied in studies examining patient-reported experiences of sleep difficulty (the Zolpidem component) was observed in numerous short-term randomized controlled trials. This research monitored objective measurements like Sleep Latency (the time it took participants to fall asleep) and Total Sleep Time. Findings describe patterns observed in the studies where the component agent data show patterns related to observed measurements in sleep parameters in the short term, generally lasting up to four to five weeks. The scientific evidence base for the hypnotic component is primarily derived from studies with short-term follow-up durations.

Research on the Dual-Agent Formulation

Zozo is a specific formulation combining an agent studied for nervous tension with an agent studied for sleep difficulty. There is a research gap for this precise fixed-dose combination product. Dedicated, controlled clinical trials specifically designed to compare this combination against its individual component agents or against placebo are limited or absent in the authoritative scientific literature.

Comparative evidence is lacking to definitively describe the patterns observed when these two specific agents are formulated together. The scientific understanding of this fixed combination as a single therapeutic product remains uncertain.

Key Studies & References Alprazolam: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Zozo (FAQ)

Q: Is Zozo an antibiotic, an anti-inflammatory, or something else?

A: According to the official product information, Zozo is classified as a Central Nervous System (CNS) depressant. This classification means it is intended to reduce activity in the brain and spinal cord. It is not an antibiotic (used to fight bacterial infections) or an anti-inflammatory drug.

Q: What is the purpose of taking Zozo?

A: Zozo is a combination of two active ingredients, each with a primary purpose. The Alprazolam component is generally indicated for the short-term relief of anxiety. The Zolpidem component is indicated for the short-term treatment of insomnia, specifically helping patients who have difficulty initiating sleep.

Q: How does Zozo actually work in the body?

A: Zozo's components work by enhancing the effects of a natural chemical in the brain called GABA (Gamma-Aminobutyric Acid). GABA is a neurotransmitter that helps calm nerve activity. By increasing GABA's effects, the medicine reduces overactive brain function, which promotes calmness and facilitates sleep.

Q: Does Zozo have a generic version available?

A: The individual active ingredients in Zozo, Alprazolam and Zolpidem, are both widely available as generic medications. The specific fixed-dose combination product may be available in generic form depending on patent status and approval.

Q: How long does it typically take for Zozo to start working?

A: Official information indicates that the Zolpidem component is characterized by a rapid onset of action, which may contribute to a quicker time to fall asleep. The Alprazolam component typically reaches its peak concentration in the blood within 1 to 2 hours after being taken orally.

Q: When should I expect to feel the full effect of Zozo?

A: The components of Zozo are absorbed relatively quickly. While some effects may be felt soon after taking a dose, the full therapeutic benefit for the underlying condition may be observed after consistent use over several days or weeks.

Q: How long does Zozo stay in your system after stopping it?

A: The time it takes for a medicine to be cleared from the system is based on its half-life. The Zolpidem component has a short half-life of about 2.6 hours, while the Alprazolam component has a longer mean half-life of approximately 11.2 hours. It takes multiple half-lives for the drug to be fully eliminated.

Q: Are there any long-term side effects associated with taking Zozo?

A: Regulatory documents include warnings about the risk of developing physical dependence and experiencing withdrawal reactions with continued use. Controlled clinical trials supporting long-term safety of use beyond several months are limited.

Q: Can Zozo affect your mood or make you feel anxious?

A: Official safety warnings indicate that Zozo's components can be associated with Abnormal Thinking and Behavioral Changes. These reported changes include a worsening of depression and, in some cases, suicidal thinking. Paradoxical reactions, such as increased agitation or aggression, have also been reported.

Q: Does Zozo interact with common over-the-counter pain relievers?

A: Regulatory information indicates that Zozo can have an additive depressant effect when taken with Other CNS Depressants, which may include certain strong pain relievers like opioids. However, no specific interactions are typically noted in the label with non-opioid, non-sedating pain relievers such as ibuprofen or acetaminophen.

Q: Do people with kidney issues need a different dose of Zozo?

A: Official labeling notes that the clearance of the Alprazolam component may be altered in patients with impaired kidney (renal) function. Dosage recommendations for this population are not as explicitly defined as for those with hepatic impairment.

Q: What happens if you stop taking Zozo suddenly?

A: Regulatory warnings state that abrupt discontinuation or rapid dose reduction of the Alprazolam component may precipitate acute withdrawal reactions. These reactions can be serious and have included symptoms such as seizures.

Q: Can you take Zozo only when you feel symptoms?

A: The Zolpidem component is indicated for short-term treatment of insomnia and is generally taken nightly. Regulatory indications suggest use for defined treatment periods, rather than strictly on an occasional, as-needed basis.

Q: What kind of research has been done on the long-term use of Zozo?

A: Clinical trials supporting the effectiveness of the components primarily focused on short-term periods—for example, up to 4 to 10 weeks for Alprazolam and up to 35 days for Zolpidem. This indicates that the primary focus of controlled trials was on short-term efficacy and safety.

Q: Where can I find reliable clinical trial results for Zozo?

A: Summaries of the clinical trial results and supporting data for the active components can be found within the Clinical Studies section of the full prescribing information. This information is published on government drug information sites like DailyMed or the FDA.

Q: Why do some people say Zozo makes them feel tired?

A: The sensation of being tired or drowsy is a frequently reported effect of this medication. Official adverse reaction data for both components lists somnolence (drowsiness), dizziness, and fatigue as common side effects, reflecting the drug's fundamental action as a CNS depressant.

Q: Can Zozo be cut in half or crushed?

A: Some forms of the Alprazolam tablet are scored and may be designed to be divided. However, the regulatory label for the Zolpidem component generally does not authorize cutting or crushing, and many products are formulated to be swallowed whole. This is especially true for extended-release forms.

Q: Is it possible to develop a tolerance to Zozo over time?

A: Yes, official warnings for both active ingredients indicate that tolerance may develop over time. Tolerance means that the same dose of the medicine may produce a reduced therapeutic effect compared to when the treatment was started.

Q: Does Zozo affect sleep patterns?

A: The Zolpidem component is specifically designed and approved to affect sleep patterns. Clinical studies show that it can significantly reduce the time it takes for patients to fall asleep (sleep latency), which is the intended therapeutic effect.

Q: What happens if you take more than the recommended amount of Zozo?

A: Taking an amount higher than recommended, particularly if combined with other CNS depressants, can result in serious consequences. Signs of overdosage can range from severe drowsiness and confusion to potentially life-threatening effects such as coma or respiratory depression.

Q: Can Zozo make an existing medical condition worse?

A: Official warnings state that Zozo may exacerbate certain pre-existing conditions. For example, the Zolpidem component may potentially worsen depression, and the Alprazolam component is officially contraindicated for patients who have acute narrow-angle glaucoma.

Q: Is Zozo a common medication?

A: While Zozo is a specific combination, its individual active ingredients are very commonly prescribed. Alprazolam and Zolpidem are both classified among the most frequently used medications within their respective drug classes.

Q: Is it better to take Zozo in the morning or at night?

A: The Zolpidem component is indicated to be taken immediately before going to bed and only when the patient is able to get a full 7 to 8 hours of sleep. This instruction is emphasized due to the risk of next-day impairment and drowsiness.

Q: Why do doctors usually start with a lower dose of Zozo?

A: Official regulatory labels recommend using the lowest possible effective dose. This is to minimize the risk of known adverse reactions, including CNS depressant effects, physical dependence, and any lingering impairment that could affect the next day.

How should Zozo be stored and disposed of?

The storage and disposal of Zozo (oral tablets/capsules) must adhere strictly to official regulatory requirements, as mandated for controlled substances.

Storage Requirements

Zozo must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept in a tightly closed container and protected from excessive heat, moisture, and direct light. It is required that the product must not be frozen.

Child Safety and Disposal

For safety, the medication must be stored out of the reach of children. The preferred method for disposal of unused or expired tablets is a drug take-back program or authorized collector. If a take-back option is unavailable, the regulatory instruction is to mix the product with an undesirable substance, seal it, and discard it in household trash; the medicine must not be flushed down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zozo found in:

A-Z Index: